Repare Ebit Per Revenue from 2010 to 2024

RPTX Stock  USD 2.81  0.16  5.39%   
Repare Therapeutics Ebit Per Revenue yearly trend continues to be fairly stable with very little volatility. Ebit Per Revenue will likely drop to -2.39 in 2024. During the period from 2010 to 2024, Repare Therapeutics Ebit Per Revenue regression line of annual values had significance of  0.0008 and arithmetic mean of (296.25). View All Fundamentals
 
Ebit Per Revenue  
First Reported
2010-12-31
Previous Quarter
(2.27)
Current Value
(2.39)
Quarterly Volatility
181.9565025
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Repare Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Repare Therapeutics' main balance sheet or income statement drivers, such as Tax Provision of 2.8 M, Interest Income of 13.8 M or Depreciation And Amortization of 1.8 M, as well as many indicators such as Price To Sales Ratio of 5.71, Dividend Yield of 0.0 or PTB Ratio of 1.52. Repare financial statements analysis is a perfect complement when working with Repare Therapeutics Valuation or Volatility modules.
  
Check out the analysis of Repare Therapeutics Correlation against competitors.
For more information on how to buy Repare Stock please use our How to Invest in Repare Therapeutics guide.

Latest Repare Therapeutics' Ebit Per Revenue Growth Pattern

Below is the plot of the Ebit Per Revenue of Repare Therapeutics over the last few years. It is Repare Therapeutics' Ebit Per Revenue historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Repare Therapeutics' overall financial position and show how it may be relating to other accounts over time.
Ebit Per Revenue10 Years Trend
Slightly volatile
   Ebit Per Revenue   
       Timeline  

Repare Ebit Per Revenue Regression Statistics

Arithmetic Mean(296.25)
Coefficient Of Variation(61.42)
Mean Deviation155.45
Median(402.24)
Standard Deviation181.96
Sample Variance33,108
Range402
R-Value0.77
Mean Square Error14,569
R-Squared0.59
Significance0.0008
Slope31.29
Total Sum of Squares463,514

Repare Ebit Per Revenue History

2024 -2.39
2023 -2.27
2022 -0.15
2021 -14.3

About Repare Therapeutics Financial Statements

Repare Therapeutics investors use historical fundamental indicators, such as Repare Therapeutics' Ebit Per Revenue, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Repare Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Ebit Per Revenue(2.27)(2.39)

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Repare Stock Analysis

When running Repare Therapeutics' price analysis, check to measure Repare Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Repare Therapeutics is operating at the current time. Most of Repare Therapeutics' value examination focuses on studying past and present price action to predict the probability of Repare Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Repare Therapeutics' price. Additionally, you may evaluate how the addition of Repare Therapeutics to your portfolios can decrease your overall portfolio volatility.